ARTICLE | Clinical News

Oral finafloxacin: Additional Phase II data

October 19, 2015 7:00 AM UTC

Additional data from 193 patients hospitalized with cUTI and pyelonephritis in the mITT population of a double-blind, double-dummy, European Phase II trial showed that 5- and 10-day regimens of once-daily 800 mg finafloxacin each met the secondary endpoint of improving the composite response rate, defined as both microbiological eradication and elimination of clinical symptoms, at the end of study visit at day 24 vs. twice-daily 400 mg ciprofloxacin for 10 days, the standard of care (73% and 62%, respectively, vs. 56%). Additionally, the 5-day regimen did not lead to an increased rate of relapses at day 24 compared to the 10-day regimen or ciprofloxacin. ...